Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells. 2010

Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland. leena.strien@hus.fi

Our aim was to compare the HER-2 and hormone receptor status between primary tumor (PT) and sentinel node (SN) metastases in breast cancer. We analyzed 65 PTs with 42 macrometastases, 18 micrometastases, and 5 ITCs for the HER-2 amplification status and for the hormone receptor status. In HER-2-positive PTs, 26 of 29 metastases were HER-2-positive, including all six analyzed micrometastases and ITCs. Three macrometastases were HER-2-negative. In HER-2-negative PTs, 35 of 36 metastases were HER-2-negative. A low-grade HER-2 amplification was detected in one micrometastasis. A full concordance between the PT and SN metastases in both HER-2 amplification and ER and PR status was observed in 40 of 56 (71%) cases. These 40 fully concordant cases included 27 macrometastatic, 9 micrometastatic, and 4 ITC-cases. The concordance in HER-2, ER, and PR was high between the PT and their SN metastases. However, the concordance may be remarkably lower when analyzed simultaneously for all three predictive factors.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D047628 Estrogen Receptor alpha One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA. ERalpha,Estradiol Receptor alpha,Estrogen Receptor 1,Estrogen Receptors alpha,Receptor alpha, Estrogen,Receptor alpha, Estradiol,alpha, Estradiol Receptor
D018270 Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST. Carcinoma, Infiltrating Duct,Carcinoma, Invasive Ductal, Breast,Carcinoma, Mammary Ductal,Invasive Ductal Carcinoma, Breast,Mammary Ductal Carcinoma,Carcinomas, Infiltrating Duct,Carcinomas, Mammary Ductal,Mammary Ductal Carcinomas

Related Publications

Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
January 2003, Journal of the National Cancer Institute,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
February 2006, Annals of surgical oncology,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
September 2003, Journal of the National Cancer Institute,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
November 2008, Journal of the National Cancer Institute,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
December 2018, BMC cancer,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
September 2011, The Ceylon medical journal,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
August 2017, Bioscience reports,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
October 2005, American journal of surgery,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
July 2016, The breast journal,
Leena Strien, and Marjut Leidenius, and Karl von Smitten, and Päivi Heikkilä
August 2018, Translational oncology,
Copied contents to your clipboard!